Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
45 articles
Newest firstMajor depressive disorder (MDD) refers to a complex mental disorder defined by hindered reward system and hindered stress resilience. The limitations of traditional monoamine antidepressants have prompted the academic community to study new pathological processes and intervention strategies. Major depressive disorder arises from a complex interplay of psychological, social, and biological factors. Among the latter…
Open article record in new tab ↗BACKGROUND: Major depressive disorder (MDD) is a chronic, recurrent psychiatric illness with challenging management, partly due to the heterogeneity of clinical presentations, unpredictable course and episodes, and variable treatment responses. Cannabis may alleviate depression by promoting glutamate, GABA, and dopamine, but results from previous studies remain controversial or inconsistent. In this study, we aime…
Open article record in new tab ↗ObjectiveAs epidemiological patterns of cannabis use and internalizing problems evolve globally, it is critical to reassess their associations-particularly in the post-legalization and post-pandemic context.MethodsParticipants were assessed in the 2012 Canadian Community Health Survey's Mental Health Component (CCHS-MH; n = 25,113) and 2022 Mental Health and Access to Care Survey (MHACS; n = 9,861), two nationally…
Major Depressive Disorder (MDD) is a severe, chronic illness for which conventional treatments often show limited efficacy and side effects, driving a renewed interest in traditional medicinal plants. The therapeutic promise of these plants lies in their multi-targeted action, influencing neurotransmitter systems, modulating neuroinflammation and oxidative stress, impacting neuroplasticity, and regulating the Hypo…
Open article record in new tab ↗Background and aims Modified Chaihu-Longgu-Muli Decoction (mCLMD) has well-established clinical antidepressant efficacy, yet its precise systemic mechanisms of action remain incompletely characterized. Here, we employed an integrated multi-omics strategy to delineate the mechanisms by which mCLMD exerts antidepressant-like effects via modulation of the gut microbiota-lipid-brain axis. Experimental procedures Rats…
Background The endocannabinoid system (ES) plays a pivotal role in modulating central nervous system activity in response to emotional stimuli. This study aimed to identify and validate biomarkers associated with ES-related genes (ES-RGs) in major depressive disorder (MDD), providing insights into potential therapeutic targets. Methods Datasets GSE52790 and GSE38206 were analyzed in this study. Overlapping differe…
Open article record in new tab ↗The role of the endocannabinoid system (ECS) in major depressive disorder (MDD) is under-investigated despite reports of increased activity and/or concentration of fatty acid amide hydrolase (FAAH), a key ECS enzyme, in fronto-limbic brain regions in some animal models of depressive behavior. We hypothesized that [11C]CURB λk3, an index of FAAH density, would be elevated in the prefrontal cortex, hippocampus, and…
Major depressive disorder (MDD) exhibits substantial neurobiological heterogeneity that complicates treatment selection and mechanistic understanding. While conventional group-level analyses identify diverse structural alterations, they obscure clinically relevant individual differences. We employed heterogeneity through discriminant analysis (HYDRA) clustering to decompose morphometric inverse divergence (MIND) n…
Pediatric major depressive disorder (MDD) represents a leading cause of disability worldwide in children and adolescents, while its underlying pathophysiology remains largely elusive. The endocannabinoid system (ECS) and the hypothalamus-pituitary-adrenal (HPA) axis are considered intertwined regulatory systems crucially implicated in the pathophysiology of depressive disorders. This study explores the cross-secti…
BackgroundMajor depressive disorder is a mood disorder with significant psychological and physical symptoms, leading to disability and severe consequences. It is influenced by genetic and environmental factors, causing neurotransmitter imbalances and inflammation. Given the high prevalence and impact, it is crucial to implement a health promotion and intervention program. Investigating the efficacy of physical the…
Background Major depressive disorder (MDD) is a highly prevalent mental health disorder with females experiencing higher rates of depression (11.6%), anxiety (15.7%) and physiological distress (14.5%) than males. Recently, the Endocannabinoid system (ECS) has been proposed to be a key contributing factor in the pathogenesis and symptom severity of MDD due to its role in neurotransmitter production, inflammatory re…
Open article record in new tab ↗Evidence from preclinical animal models suggests that the stress-buffering function of the endocannabinoid (eCB) system may help protect against stress-related reductions in hippocampal volume, as is documented in major depressive disorder (MDD). However, stress exposure may also lead to dysregulation of this system. Thus, pathways from marked stress histories, such as childhood maltreatment (CM), to smaller hippo…
Major depressive disorder (MDD) is associated with T cell activation, but no studies have examined the combined effects of T cell activation and deficits in T regulatory (Treg) cells on the severity of acute phase MDD. Using flow cytometry, we determined the percentage and median fluorescence intensity of CD69, CD71, CD40L, and HLADR-bearing CD3+, CD4+, and CD8+ cells, and cannabinoid type 1 receptor (CB1), CD152…
Open article record in new tab ↗Background Problematic cannabis use is highly prevalent among people with mood disorders. This underscores the need to understand the effects of cannabis and cannabinoids in this population, especially considering legalization of recreational cannabis use. Objectives We aimed to (1) systematically evaluate cross-sectional and longitudinal studies investigating the interplay between cannabis use, cannabis use disor…
Open article record in new tab ↗Genetic contributions to human cortical structure manifest pervasive pleiotropy. This pleiotropy may be harnessed to identify unique genetically-informed parcellations of the cortex that are neurobiologically distinct from functional, cytoarchitectural, or other cortical parcellation schemes. We investigated genetic pleiotropy by applying genomic structural equation modeling (SEM) to map the genetic architecture o…
Background: The transnosographic nature of negative symptoms (NS) makes them fruitful for detecting psychiatric symptoms. The main objective of this study was to determine whether NS can be useful in screening for ultra-high risk of psychosis (UHR) or depressive symptoms in the no-help-seeking student population. The most prevalent NS and their relationship with cannabis use were also researched. Methods: From an…
Open article record in new tab ↗Background Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are two high-prevalent conditions where the Endocannabinoid system (ECS) is believed to play an important role. The ECS regulates how different neurotransmitters interact in both disorders, which is crucial for controlling emotions and responses to stress and reward stimuli. Measuring peripheral endocannabinoids (eCBs) in human serum and pla…
Open article record in new tab ↗Background The retrograde endocannabinoid (eCB) pathway is closely associated with the etiology of major depressive disorder (MDD) at both pathophysiological and genetic levels. This study aimed to investigate the potential role of genetic mutations in the eCB pathway and underlying mechanisms in Han Chinese patients with MDD. Methods A total of 96 drug-naïve patients with first-episode MDD and 62 healthy controls…
Open article record in new tab ↗